Monsanto, Sankyo deal

Monsanto's Searle subsidiary (Chicago) and Sankyo will co-develop xemilofiban, Searle's oral antiplatelet agent, in Japan. Sankyo (Tokyo) will pay an undisclosed one-time license fee, milestone payments and royalties, as well as purchase compound from Searle. ...